RECOVERY AND ELIMINATION OF THE BIOTHERAPEUTIC AGENT, SACCHAROMYCES-BOULARDII, IN HEALTHY-HUMAN VOLUNTEERS

被引:59
作者
KLEIN, SM
ELMER, GW
MCFARLAND, LV
SURAWICZ, CM
LEVY, RH
机构
[1] UNIV WASHINGTON,DEPT MED CHEM,BG-20,SEATTLE,WA 98195
[2] UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT MED,SEATTLE,WA 98104
[3] UNIV WASHINGTON,DEPT PHARMACEUT,SEATTLE,WA 98195
关键词
SACCHAROMYCES-BOULARDII; ANTIBIOTICS; GASTROINTESTINAL KINETICS; DOSE; RECOVERY; BIOTHERAPEUTIC AGENT;
D O I
10.1023/A:1018924820333
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Saccharomyces boulardii (Sb) is a nonpathogenic yeast used to treat intestinal illnesses such as pseudomembranous colitis and antibiotic associated diarrhea. The behavior of this biotherapeutic agent in humans was determined (1) in investigating the effect of dose on the steady-state level and recovery and (2) in quantitating the effect of ampicillin on the recovery and elimination profile. As the Sb dose increased, the mean steady-state concentration of Sb increased significantly. The percentage recovery was dose independent. When a single Sb dose was administered 24 hr after beginning a course of ampicillin, there was a significant increase (P < 0.01) in both the area under the concentration versus time curve and the maximum fecal concentration compared to values obtained without ampicillin. Ampicillin increased steady-state recovery of the drug about twofold (P < 0.05) and steady-state levels about 2.4 times (P < 0.01). These studies have shown that there is a relationship between the dose and the amount of Sb recovered and that perturbation of the GI flora by ampicillin increases steady-state levels of Sb.
引用
收藏
页码:1615 / 1619
页数:5
相关论文
共 14 条
[1]   DISPOSITION KINETICS OF SACCHAROMYCES-BOULARDII IN MAN AND RAT [J].
BLEHAUT, H ;
MASSOT, J ;
ELMER, GW ;
LEVY, RH .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1989, 10 (04) :353-364
[2]   INFLUENCE OF ANTIBIOTICS ON THE RECOVERY AND KINETICS OF SACCHAROMYCES-BOULARDII IN RATS [J].
BODDY, AV ;
ELMER, GW ;
MCFARLAND, LV ;
LEVY, RH .
PHARMACEUTICAL RESEARCH, 1991, 8 (06) :796-800
[3]  
ELMER GW, 1990, CAN J MICROBIOL, V37, P315
[4]   PROBIOTICS IN HUMAN MEDICINE [J].
FULLER, R .
GUT, 1991, 32 (04) :439-442
[5]   SURVIVAL OF LACTOBACILLUS SPECIES (STRAIN GG) IN HUMAN GASTROINTESTINAL-TRACT [J].
GOLDIN, BR ;
GORBACH, SL ;
SAXELIN, M ;
BARAKAT, S ;
GUALTIERI, L ;
SALMINEN, S .
DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (01) :121-128
[6]  
GORBACH SL, 1987, LANCET, V2, P1519
[7]   ENZYME-SUBSTITUTION THERAPY WITH THE YEAST SACCHAROMYCES-CEREVISIAE IN CONGENITAL SUCRASE ISOMALTASE DEFICIENCY [J].
HARMS, HK ;
BERTELEHARMS, RM ;
BRUERKLEIS, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (21) :1306-1309
[8]   PREVENTION OF FURTHER RECURRENCES OF CLOSTRIDIUM-DIFFICILE COLITIS WITH SACCHAROMYCES-BOULARDII [J].
KIMMEY, MB ;
ELMER, GW ;
SURAWICZ, CM ;
MCFARLAND, LV .
DIGESTIVE DISEASES AND SCIENCES, 1990, 35 (07) :897-901
[9]   IMPACT OF ANTIMICROBIAL AGENTS ON HUMAN INTESTINAL MICROFLORA [J].
NORD, CE ;
EDLUND, C .
JOURNAL OF CHEMOTHERAPY, 1990, 2 (04) :218-237
[10]   KINETICS OF SACCHAROMYCES-CEREVISIAE ELIMINATION FROM THE INTESTINES OF HUMAN VOLUNTEERS AND EFFECT OF THIS YEAST ON RESISTANCE TO MICROBIAL COLONIZATION IN GNOTOBIOTIC MICE [J].
PECQUET, S ;
GUILLAUMIN, D ;
TANCREDE, C ;
ANDREMONT, A .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1991, 57 (10) :3049-3051